These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 26845112)
1. Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care. van Wanrooy MJ; Rodgers MG; Span LF; Zijlstra JG; Uges DR; Kosterink JG; van der Werf TS; Alffenaar JW Ther Drug Monit; 2016 Jun; 38(3):313-8. PubMed ID: 26845112 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring and safety of voriconazole in elderly patients. Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620 [TBL] [Abstract][Full Text] [Related]
3. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis. Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015 [TBL] [Abstract][Full Text] [Related]
4. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old. Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272 [TBL] [Abstract][Full Text] [Related]
5. Bioavailability of voriconazole in hospitalised patients. Veringa A; Geling S; Span LF; Vermeulen KM; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JC Int J Antimicrob Agents; 2017 Feb; 49(2):243-246. PubMed ID: 28012684 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study. Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038 [TBL] [Abstract][Full Text] [Related]
8. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. Boast A; Curtis N; Cranswick N; Gwee A J Antimicrob Chemother; 2016 Jul; 71(7):2031-6. PubMed ID: 27009030 [TBL] [Abstract][Full Text] [Related]
9. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C). Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306 [TBL] [Abstract][Full Text] [Related]
10. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246 [TBL] [Abstract][Full Text] [Related]
11. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China. Liu L; Zhou X; Wu T; Jiang H; Yang S; Zhang Y Int J Antimicrob Agents; 2017 Apr; 49(4):483-487. PubMed ID: 28159657 [TBL] [Abstract][Full Text] [Related]
12. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261 [TBL] [Abstract][Full Text] [Related]
13. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China. Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475 [TBL] [Abstract][Full Text] [Related]
15. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy. Kadam RS; Van Den Anker JN Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736 [TBL] [Abstract][Full Text] [Related]
16. Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. Vanstraelen K; Maertens J; Augustijns P; Lagrou K; de Loor H; Mols R; Annaert P; Malfroot A; Spriet I Clin Pharmacokinet; 2015 Nov; 54(11):1151-60. PubMed ID: 25910879 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Empiric Voriconazole Dosing and Therapeutic Drug Monitoring in Hospitalized Pediatric Patients. Schweiger JA; Heiden AM; MacBrayne CE J Pediatr Hematol Oncol; 2024 Aug; 46(6):e419-e425. PubMed ID: 38934583 [TBL] [Abstract][Full Text] [Related]
18. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations. You H; Dong Y; Zou Y; Zhang T; Lei J; Chen L; Wang X; Dong Y; Wang T Int J Clin Pharmacol Ther; 2018 May; 56(5):239-246. PubMed ID: 29393850 [TBL] [Abstract][Full Text] [Related]
19. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study. Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604 [TBL] [Abstract][Full Text] [Related]
20. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Howard A; Hoffman J; Sheth A Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]